In our study, we assessed the concentrations of RTN-4 in CSF patients with two of the most common neurodegenerative diseases, such as AD and PD, subjects with the neurological disease in which cognitive impairment develops (MS), and control group (i.e., individuals without cognitive decline). The gene discussed is RTN4; the disease is myeloid sarcoma.